25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AGIO (Agios) Stock Analysis
Buy, Hold or Sell?

Let's analyze Agios together

I guess you are interested in Agios Pharm. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Agios’s Financial Insights
  • 📈 Technical Analysis (TA) – Agios’s Price Targets

I'm going to help you getting a better view of Agios Pharm. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Agios Pharm

I send you an email if I find something interesting about Agios Pharm.

1. Quick Overview

1.1. Quick analysis of Agios (30 sec.)










1.2. What can you expect buying and holding a share of Agios? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$25.32
Expected worth in 1 year
$37.80
How sure are you?
17.5%

+ What do you gain per year?

Total Gains per Share
$12.48
Return On Investment
32.0%

For what price can you sell your share?

Current Price per Share
$39.05
Expected price per share
$32.90 - $62.45
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Agios (5 min.)




Live pricePrice per Share (EOD)
$39.05
Intrinsic Value Per Share
$-64.66 - $-52.83
Total Value Per Share
$-39.33 - $-27.51

2.2. Growth of Agios (5 min.)




Is Agios growing?

Current yearPrevious yearGrowGrow %
How rich?$1.4b$851.5m$472.1m35.7%

How much money is Agios making?

Current yearPrevious yearGrowGrow %
Making money$166.4m-$88.1m$254.6m152.9%
Net Profit Margin1,884.0%-1,207.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Agios (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Agios?

Welcome investor! Agios's management wants to use your money to grow the business. In return you get a share of Agios.

First you should know what it really means to hold a share of Agios. And how you can make/lose money.

Speculation

The Price per Share of Agios is $39.05. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Agios.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Agios, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $25.32. Based on the TTM, the Book Value Change Per Share is $3.12 per quarter. Based on the YOY, the Book Value Change Per Share is $-1.26 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Agios.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.54-3.9%2.847.3%-1.52-3.9%0.130.3%0.902.3%-0.15-0.4%
Usd Book Value Change Per Share-1.29-3.3%3.128.0%-1.26-3.2%0.371.0%0.812.1%0.451.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.29-3.3%3.128.0%-1.26-3.2%0.371.0%0.812.1%0.451.1%
Usd Price Per Share29.30-37.43-26.15-29.65-35.12-47.05-
Price to Earnings Ratio-4.75--3.87--4.34--2.86--4.23--9.51-
Price-to-Total Gains Ratio-22.80--19.18--20.86--15.53--18.27--42.19-
Price to Book Ratio1.16-1.94-1.80-1.70-2.39-4.89-
Price-to-Total Gains Ratio-22.80--19.18--20.86--15.53--18.27--42.19-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share39.05
Number of shares25
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share3.120.81
Usd Total Gains Per Share3.120.81
Gains per Quarter (25 shares)77.9820.26
Gains per Year (25 shares)311.9281.04
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1031230208171
206246140162152
309369260243233
40124812380324314
50156015500405395
60187218620486476
70218321740567557
80249524860648638
90280727980729719
100311931100810800

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%3.037.00.07.5%4.049.01.07.4%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%7.033.00.017.5%13.038.03.024.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.054.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%3.017.00.015.0%7.033.00.017.5%13.038.03.024.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Agios Pharm compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.2853.119-141%-1.263-2%0.373-445%0.810-259%0.449-386%
Book Value Per Share--25.32222.793+11%14.703+72%18.702+35%18.685+36%13.646+86%
Current Ratio--18.49712.370+50%12.724+45%13.654+35%15.372+20%11.233+65%
Debt To Asset Ratio--0.0570.092-38%0.123-53%0.107-46%0.158-64%0.220-74%
Debt To Equity Ratio--0.0610.103-41%0.140-57%0.120-50%0.236-74%0.330-82%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--2501300360.0002891576845.570-13%2194446404.000+14%2421024899.857+3%2943344633.381-15%3380917362.789-26%
Eps---1.5422.839-154%-1.522-1%0.125-1333%0.904-271%-0.154-90%
Ev To Ebitda Ratio---5.864-6.678+14%-5.715-3%-6.094+4%-7.798+33%-11.862+102%
Ev To Sales Ratio--71.66278.885-9%75.181-5%91.221-21%967421.805-100%471346.424-100%
Free Cash Flow Per Share---1.938-1.740-10%-1.377-29%-1.484-23%-1.453-25%-1.202-38%
Free Cash Flow To Equity Per Share---1.910-1.696-11%-1.339-30%-1.452-24%-1.886-1%-0.869-54%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.005-1%
Intrinsic Value_10Y_max---52.831----------
Intrinsic Value_10Y_min---64.655----------
Intrinsic Value_1Y_max---4.886----------
Intrinsic Value_1Y_min---6.067----------
Intrinsic Value_3Y_max---14.991----------
Intrinsic Value_3Y_min---18.694----------
Intrinsic Value_5Y_max---25.472----------
Intrinsic Value_5Y_min---31.733----------
Market Cap2261588560.000+25%1696915360.0002173370345.570-22%1514192904.000+12%1719053816.523-1%2147854233.381-21%2801792637.789-39%
Net Profit Margin---10.23318.840-154%-12.074+18%1.438-812%-114258.895+1116525%-57131.948+558237%
Operating Margin----8.8890%-13.5490%-14.5450%-129495.1320%-64750.1270%
Operating Ratio--13.22012.906+2%14.451-9%16.333-19%132155.040-100%66082.377-100%
Pb Ratio1.542+25%1.1571.942-40%1.796-36%1.701-32%2.394-52%4.891-76%
Pe Ratio-6.332-33%-4.751-3.873-18%-4.342-9%-2.862-40%-4.230-11%-9.513+100%
Price Per Share39.050+25%29.30037.428-22%26.145+12%29.649-1%35.124-17%47.053-38%
Price To Free Cash Flow Ratio-5.037-33%-3.779-5.894+56%-4.829+28%-5.205+38%-6.516+72%-15.403+308%
Price To Total Gains Ratio-30.386-33%-22.799-19.181-16%-20.865-8%-15.527-32%-18.266-20%-42.185+85%
Quick Ratio--32.67621.361+53%23.967+36%24.812+32%26.266+24%19.348+69%
Return On Assets---0.0570.072-179%-0.092+60%-0.011-80%0.003-1817%-0.049-15%
Return On Equity---0.0610.078-178%-0.104+72%-0.014-77%-0.011-82%-0.079+29%
Total Gains Per Share---1.2853.119-141%-1.263-2%0.373-445%0.810-259%0.449-386%
Usd Book Value--1466528000.0001323666500.000+11%851505000.000+72%1084355500.000+35%1118165950.000+31%812874225.000+80%
Usd Book Value Change Per Share---1.2853.119-141%-1.263-2%0.373-445%0.810-259%0.449-386%
Usd Book Value Per Share--25.32222.793+11%14.703+72%18.702+35%18.685+36%13.646+86%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--2501300360.0002891576845.570-13%2194446404.000+14%2421024899.857+3%2943344633.381-15%3380917362.789-26%
Usd Eps---1.5422.839-154%-1.522-1%0.125-1333%0.904-271%-0.154-90%
Usd Free Cash Flow---112255000.000-100943250.000-10%-79746750.000-29%-86013500.000-23%-87080850.000-22%-71864325.000-36%
Usd Free Cash Flow Per Share---1.938-1.740-10%-1.377-29%-1.484-23%-1.453-25%-1.202-38%
Usd Free Cash Flow To Equity Per Share---1.910-1.696-11%-1.339-30%-1.452-24%-1.886-1%-0.869-54%
Usd Market Cap2261588560.000+25%1696915360.0002173370345.570-22%1514192904.000+12%1719053816.523-1%2147854233.381-21%2801792637.789-39%
Usd Price Per Share39.050+25%29.30037.428-22%26.145+12%29.649-1%35.124-17%47.053-38%
Usd Profit---89289000.000166496250.000-154%-88154750.000-1%20829750.000-529%73957750.000-221%1387075.000-6537%
Usd Revenue--8726000.0009258750.000-6%7350750.000+19%7121250.000+23%14057052.071-38%17958951.035-51%
Usd Total Gains Per Share---1.2853.119-141%-1.263-2%0.373-445%0.810-259%0.449-386%
 EOD+5 -3MRQTTM+11 -25YOY+19 -173Y+15 -215Y+13 -2310Y+14 -23

3.3 Fundamental Score

Let's check the fundamental score of Agios Pharm based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.332
Price to Book Ratio (EOD)Between0-11.542
Net Profit Margin (MRQ)Greater than0-10.233
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than132.676
Current Ratio (MRQ)Greater than118.497
Debt to Asset Ratio (MRQ)Less than10.057
Debt to Equity Ratio (MRQ)Less than10.061
Return on Equity (MRQ)Greater than0.15-0.061
Return on Assets (MRQ)Greater than0.05-0.057
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Agios Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.000
Ma 20Greater thanMa 5035.197
Ma 50Greater thanMa 10032.497
Ma 100Greater thanMa 20031.535
OpenGreater thanClose38.850
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Agios Pharm

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2025-07-10 20:07:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Agios earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Agios to the Biotechnology industry mean.
  • A Net Profit Margin of -1,023.3% means that $-10.23 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Agios Pharm:

  • The MRQ is -1,023.3%. The company is making a huge loss. -2
  • The TTM is 1,884.0%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ-1,023.3%TTM1,884.0%-2,907.3%
TTM1,884.0%YOY-1,207.4%+3,091.4%
TTM1,884.0%5Y-11,425,889.5%+11,427,773.6%
5Y-11,425,889.5%10Y-5,713,194.8%-5,712,694.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,023.3%-91.7%-931.6%
TTM1,884.0%-140.3%+2,024.3%
YOY-1,207.4%-196.4%-1,011.0%
3Y143.8%-247.9%+391.7%
5Y-11,425,889.5%-343.3%-11,425,546.2%
10Y-5,713,194.8%-488.1%-5,712,706.7%
4.3.1.2. Return on Assets

Shows how efficient Agios is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Agios to the Biotechnology industry mean.
  • -5.7% Return on Assets means that Agios generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Agios Pharm:

  • The MRQ is -5.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 7.2%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ-5.7%TTM7.2%-13.0%
TTM7.2%YOY-9.2%+16.4%
TTM7.2%5Y0.3%+6.9%
5Y0.3%10Y-4.9%+5.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.7%-11.5%+5.8%
TTM7.2%-11.5%+18.7%
YOY-9.2%-11.4%+2.2%
3Y-1.1%-11.7%+10.6%
5Y0.3%-11.9%+12.2%
10Y-4.9%-13.7%+8.8%
4.3.1.3. Return on Equity

Shows how efficient Agios is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Agios to the Biotechnology industry mean.
  • -6.1% Return on Equity means Agios generated $-0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Agios Pharm:

  • The MRQ is -6.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 7.8%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ-6.1%TTM7.8%-13.9%
TTM7.8%YOY-10.4%+18.3%
TTM7.8%5Y-1.1%+9.0%
5Y-1.1%10Y-7.9%+6.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.1%-13.6%+7.5%
TTM7.8%-14.8%+22.6%
YOY-10.4%-14.4%+4.0%
3Y-1.4%-16.8%+15.4%
5Y-1.1%-17.5%+16.4%
10Y-7.9%-19.5%+11.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Agios Pharm.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Agios is operating .

  • Measures how much profit Agios makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Agios to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Agios Pharm:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-888.9%+888.9%
TTM-888.9%YOY-1,354.9%+466.1%
TTM-888.9%5Y-12,949,513.2%+12,948,624.4%
5Y-12,949,513.2%10Y-6,475,012.7%-6,474,500.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--221.8%+221.8%
TTM-888.9%-250.7%-638.2%
YOY-1,354.9%-208.5%-1,146.4%
3Y-1,454.5%-220.2%-1,234.3%
5Y-12,949,513.2%-342.4%-12,949,170.8%
10Y-6,475,012.7%-462.5%-6,474,550.2%
4.3.2.2. Operating Ratio

Measures how efficient Agios is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 13.22 means that the operating costs are $13.22 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Agios Pharm:

  • The MRQ is 13.220. The company is inefficient in keeping operating costs low. -1
  • The TTM is 12.906. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ13.220TTM12.906+0.313
TTM12.906YOY14.451-1.544
TTM12.9065Y132,155.040-132,142.134
5Y132,155.04010Y66,082.377+66,072.663
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.2202.097+11.123
TTM12.9062.684+10.222
YOY14.4513.076+11.375
3Y16.3333.524+12.809
5Y132,155.0404.724+132,150.316
10Y66,082.3776.445+66,075.932
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Agios Pharm.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Agios is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 18.50 means the company has $18.50 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Agios Pharm:

  • The MRQ is 18.497. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.370. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ18.497TTM12.370+6.127
TTM12.370YOY12.724-0.354
TTM12.3705Y15.372-3.002
5Y15.37210Y11.233+4.139
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.4973.638+14.859
TTM12.3703.846+8.524
YOY12.7244.140+8.584
3Y13.6544.688+8.966
5Y15.3725.722+9.650
10Y11.2336.144+5.089
4.4.3.2. Quick Ratio

Measures if Agios is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Agios to the Biotechnology industry mean.
  • A Quick Ratio of 32.68 means the company can pay off $32.68 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Agios Pharm:

  • The MRQ is 32.676. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 21.361. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ32.676TTM21.361+11.315
TTM21.361YOY23.967-2.606
TTM21.3615Y26.266-4.905
5Y26.26610Y19.348+6.918
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ32.6762.826+29.850
TTM21.3613.116+18.245
YOY23.9673.786+20.181
3Y24.8124.311+20.501
5Y26.2665.702+20.564
10Y19.3486.335+13.013
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Agios Pharm.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Agios assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Agios to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.06 means that Agios assets are financed with 5.7% credit (debt) and the remaining percentage (100% - 5.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Agios Pharm:

  • The MRQ is 0.057. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.092. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.057TTM0.092-0.035
TTM0.092YOY0.123-0.030
TTM0.0925Y0.158-0.066
5Y0.15810Y0.220-0.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0570.327-0.270
TTM0.0920.349-0.257
YOY0.1230.332-0.209
3Y0.1070.340-0.233
5Y0.1580.346-0.188
10Y0.2200.378-0.158
4.5.4.2. Debt to Equity Ratio

Measures if Agios is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Agios to the Biotechnology industry mean.
  • A Debt to Equity ratio of 6.1% means that company has $0.06 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Agios Pharm:

  • The MRQ is 0.061. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.103. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.061TTM0.103-0.042
TTM0.103YOY0.140-0.037
TTM0.1035Y0.236-0.133
5Y0.23610Y0.330-0.094
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0610.383-0.322
TTM0.1030.438-0.335
YOY0.1400.414-0.274
3Y0.1200.450-0.330
5Y0.2360.457-0.221
10Y0.3300.512-0.182
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Agios generates.

  • Above 15 is considered overpriced but always compare Agios to the Biotechnology industry mean.
  • A PE ratio of -4.75 means the investor is paying $-4.75 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Agios Pharm:

  • The EOD is -6.332. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.751. Based on the earnings, the company is expensive. -2
  • The TTM is -3.873. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.332MRQ-4.751-1.581
MRQ-4.751TTM-3.873-0.878
TTM-3.873YOY-4.342+0.470
TTM-3.8735Y-4.230+0.358
5Y-4.23010Y-9.513+5.282
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.332-2.399-3.933
MRQ-4.751-2.092-2.659
TTM-3.873-2.625-1.248
YOY-4.342-3.784-0.558
3Y-2.862-3.762+0.900
5Y-4.230-6.363+2.133
10Y-9.513-7.055-2.458
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Agios Pharm:

  • The EOD is -5.037. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.779. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.894. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.037MRQ-3.779-1.258
MRQ-3.779TTM-5.894+2.115
TTM-5.894YOY-4.829-1.065
TTM-5.8945Y-6.516+0.622
5Y-6.51610Y-15.403+8.887
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.037-3.299-1.738
MRQ-3.779-2.742-1.037
TTM-5.894-3.801-2.093
YOY-4.829-4.402-0.427
3Y-5.205-5.140-0.065
5Y-6.516-8.483+1.967
10Y-15.403-9.296-6.107
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Agios is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.16 means the investor is paying $1.16 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Agios Pharm:

  • The EOD is 1.542. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.157. Based on the equity, the company is underpriced. +1
  • The TTM is 1.942. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.542MRQ1.157+0.385
MRQ1.157TTM1.942-0.785
TTM1.942YOY1.796+0.146
TTM1.9425Y2.394-0.451
5Y2.39410Y4.891-2.497
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.5422.113-0.571
MRQ1.1571.856-0.699
TTM1.9422.125-0.183
YOY1.7962.454-0.658
3Y1.7012.492-0.791
5Y2.3943.668-1.274
10Y4.8914.364+0.527
4.6.2. Total Gains per Share

2.4. Latest News of Agios Pharm

Does Agios Pharm still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Agios Pharm to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-11
23:02
Agios pharma chief medical officer Gheuens sells $452,601 in stockRead
2025-06-26
23:30
Agios pharma chief legal officer Burns sells $93k in stockRead
2025-06-17
13:36
Agios' PYRUKYND Faces FDA Review In September - Expansion Opportunity Ahead?Read
2025-06-15
11:43
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PTRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Agios Pharm.

4.8.1. Institutions holding Agios Pharm

Institutions are holding 101.395% of the shares of Agios Pharm.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Farallon Capital Management, L.L.C.9.84280.93125700466260000.4582
2025-03-31Vanguard Group Inc9.67720.0035604591-26730-0.4747
2025-03-31BlackRock Inc8.82110.00315108746924861.8437
2025-03-31Bellevue Group AG6.06952.3078351515000
2025-03-31State Street Corp4.22940.003244947929720213.8087
2025-03-31T. Rowe Price Associates, Inc.3.97370.00832301353-122184-5.0416
2025-03-31Erste Asset Management GmbH3.85030.84222990022000010.9458
2025-03-31COMMODORE CAPITAL LP3.77284.7175218500021850000
2025-03-31Armistice Capital, LLC3.53620.89932048000-216304-9.5528
2025-03-31Macquarie Group Ltd3.19530.070818505441655519.825
2025-03-31Geode Capital Management, LLC2.4080.00321394581449303.329
2025-03-31Dimensional Fund Advisors, Inc.2.17920.00921262073-66992-5.0405
2025-03-31Bank of America Corp1.96080.00271135592730690180.461
2025-03-31JPMorgan Chase & Co1.81190.00231049360340003.3486
2025-03-31BNP Paribas Investment Partners SA1.77110.08061025719835308.8655
2025-03-31Polar Capital Holdings PLC1.73020.1788100203637500059.8052
2025-03-31Fisher Asset Management, LLC1.65650.0122959339-1322-0.1376
2025-03-31Deutsche Bank AG1.6040.0108928970-6282-0.6717
2025-03-31Citadel Advisors Llc1.4910.0048863499-570177-39.7703
2025-03-31ArrowMark Colorado Holdings, LLC (ArrowMark Partners)1.4290.3927827623-89797-9.788
Total 75.0110.481343442021+3154601+7.3%

4.9.2. Funds holding Agios Pharm

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31BB Biotech AG Ord6.06954.53883515150-220765-5.9093
2025-05-31Vanguard Total Stock Mkt Idx Inv3.17490.0032183876616780.0913
2025-04-30Macquarie Small Cap Core I2.65450.68371537387213471.4081
2025-05-31Vanguard Small Cap Index2.49680.0311144603153200.3693
2025-05-31iShares Russell 2000 ETF2.45360.0741142099700
2025-05-31SPDR® S&P Biotech ETF1.86030.7369107740463700.5948
2025-03-31T. Rowe Price Health Sciences1.82530.25121057121-56528-5.0759
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr1.55190.026489880263190.708
2025-04-30DWS Vermögensbildungsfonds I LD1.39090.15805517-4-0.0005
2025-05-31Vanguard Small Cap Growth Index Inv1.37090.072793940-6825-0.8523
2025-03-31Fidelity Small Cap Index0.97590.068556520841730.7438
2025-04-30BNP Paribas Health Cr Innovtr Cl Cap0.94110.8976545034260.0048
2025-05-31iShares Russell 2000 Value ETF0.88410.153151202900
2025-03-31Vanguard Explorer Inv0.86390.0739500306-15254-2.9587
2025-05-31JPM Global Healthcare C (acc) USD0.85150.4494493165-4602-0.9245
2025-04-30BNP Paribas US Small Cap Classic R0.73030.9339422962-61861-12.7595
2025-03-31US Small-Cap Growth II Equity Comp0.72180.0761418045-63777-13.2366
2025-03-31T. Rowe Price New Horizons0.72180.0761418045-5654-1.3344
2024-10-15Pictet Biopharmaceutical Mother0.67251.2676389500-104576-21.166
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.56590.0256327719101003.1799
Total 32.777410.589218983128-484513-2.6%

5.3. Insider Transactions

Insiders are holding 1.654% of the shares of Agios Pharm.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-07-01Sarah GheuensSELL409134.17
2025-06-24Brian GoffSELL1870033.54
2025-06-24Cecilia JonesSELL178033.54
2025-06-24James William BurnsSELL279933.54
2025-06-24Sarah GheuensSELL290933.54
2025-06-24Tsveta MilanovaSELL277033.54
2025-04-10Jacqualyn A FouseSELL749725.9
2025-01-06Tsveta MilanovaSELL280432.18
2024-12-11David ScaddenSELL20046.28
2024-09-26Cecilia JonesSELL254249.03
2024-08-08Brian GoffSELL1109142.75
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,555,518
Total Liabilities88,990
Total Stockholder Equity1,466,528
 As reported
Total Liabilities 88,990
Total Stockholder Equity+ 1,466,528
Total Assets = 1,555,518

Assets

Total Assets1,555,518
Total Current Assets968,616
Long-term Assets586,902
Total Current Assets
Cash And Cash Equivalents 78,964
Short-term Investments 814,411
Net Receivables 3,344
Inventory 29,605
Other Current Assets 42,292
Total Current Assets  (as reported)968,616
Total Current Assets  (calculated)968,616
+/-0
Long-term Assets
Property Plant Equipment 50,928
Long Term Investments 531,253
Long-term Assets  (as reported)586,902
Long-term Assets  (calculated)582,181
+/- 4,721

Liabilities & Shareholders' Equity

Total Current Liabilities52,366
Long-term Liabilities36,624
Total Stockholder Equity1,466,528
Total Current Liabilities
Short-term Debt 17,196
Accounts payable 13,726
Other Current Liabilities 20,761
Total Current Liabilities  (as reported)52,366
Total Current Liabilities  (calculated)51,683
+/- 683
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt35,744
Long-term Liabilities Other 880
Long-term Liabilities  (as reported)36,624
Long-term Liabilities  (calculated)36,624
+/-0
Total Stockholder Equity
Common Stock74
Retained Earnings -238,213
Accumulated Other Comprehensive Income 365
Other Stockholders Equity 1,704,302
Total Stockholder Equity (as reported)1,466,528
Total Stockholder Equity (calculated)1,466,528
+/-0
Other
Capital Stock74
Cash and Short Term Investments 893,375
Common Stock Shares Outstanding 57,459
Liabilities and Stockholders Equity 1,555,518
Net Debt -26,024
Net Invested Capital 1,466,528
Net Working Capital 916,250
Property Plant and Equipment Gross 50,928
Short Long Term Debt Total 52,940



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
194,470
0
0
0
137,008
125,853
111,252
219,069
201,205
181,912
272,030
269,608
491,904
474,336
474,383
449,086
420,065
396,117
557,601
672,042
619,094
557,316
760,600
687,200
614,397
1,040,126
998,235
929,079
858,457
822,131
783,870
698,616
890,741
799,738
976,141
908,449
852,952
2,488,434
1,874,603
1,541,498
1,437,736
1,335,859
1,252,467
1,180,320
1,238,718
1,151,298
1,085,153
1,007,258
937,118
849,709
773,063
1,791,794
1,663,199
1,555,518
1,555,5181,663,1991,791,794773,063849,709937,1181,007,2581,085,1531,151,2981,238,7181,180,3201,252,4671,335,8591,437,7361,541,4981,874,6032,488,434852,952908,449976,141799,738890,741698,616783,870822,131858,457929,079998,2351,040,126614,397687,200760,600557,316619,094672,042557,601396,117420,065449,086474,383474,336491,904269,608272,030181,912201,205219,069111,252125,853137,008000194,470
   > Total Current Assets 
0
0
0
0
130,144
118,347
102,533
198,818
169,747
172,417
245,163
247,560
359,546
364,141
390,152
371,660
337,329
329,469
484,159
600,943
559,892
506,866
604,681
528,307
445,261
802,993
753,782
695,542
613,780
557,095
533,705
490,144
611,704
587,274
846,355
669,086
636,677
2,355,114
1,702,562
1,305,285
1,064,231
975,145
870,007
784,935
832,772
791,656
757,239
704,352
833,835
663,627
632,127
1,074,189
965,600
968,616
968,616965,6001,074,189632,127663,627833,835704,352757,239791,656832,772784,935870,007975,1451,064,2311,305,2851,702,5622,355,114636,677669,086846,355587,274611,704490,144533,705557,095613,780695,542753,782802,993445,261528,307604,681506,866559,892600,943484,159329,469337,329371,660390,152364,141359,546247,560245,163172,417169,747198,818102,533118,347130,1440000
       Cash And Cash Equivalents 
117,661
0
0
0
91,297
83,377
77,481
106,011
71,560
32,837
108,247
70,049
14,031
439,964
434,037
407,986
375,907
355,754
512,295
285,502
573,564
200,278
138,717
132,741
567,750
994,747
210,323
156,478
805,421
103,443
83,580
81,709
80,931
89,093
295,858
104,855
127,436
1,888,025
969,124
400,224
203,126
80,026
88,543
122,449
139,259
104,139
84,753
64,333
88,205
118,764
84,518
253,730
76,247
78,964
78,96476,247253,73084,518118,76488,20564,33384,753104,139139,259122,44988,54380,026203,126400,224969,1241,888,025127,436104,855295,85889,09380,93181,70983,580103,443805,421156,478210,323994,747567,750132,741138,717200,278573,564285,502512,295355,754375,907407,986434,037439,96414,03170,049108,24732,83771,560106,01177,48183,37791,297000117,661
       Short-term Investments 
61,507
0
0
0
36,679
32,374
21,794
88,945
95,209
129,432
130,233
149,921
328,034
309,450
297,261
272,317
245,238
273,859
231,321
293,595
380,560
279,480
447,325
375,187
321,212
417,981
506,582
513,414
514,800
421,114
411,810
370,188
483,946
439,528
494,270
500,684
445,493
447,578
703,864
865,833
816,892
843,503
730,766
605,231
643,860
635,062
617,813
583,155
688,723
479,227
485,374
751,027
817,463
814,411
814,411817,463751,027485,374479,227688,723583,155617,813635,062643,860605,231730,766843,503816,892865,833703,864447,578445,493500,684494,270439,528483,946370,188411,810421,114514,800513,414506,582417,981321,212375,187447,325279,480380,560293,595231,321273,859245,238272,317297,261309,450328,034149,921130,233129,43295,20988,94521,79432,37436,67900061,507
       Net Receivables 
0
0
0
0
0
0
1,247
1,246
476
2,619
3,841
22,600
6,492
13,923
15,756
12,070
11,599
7,385
9,867
11,569
8,314
14,717
5,621
5,063
3,839
4,929
21,339
8,329
10,442
10,514
14,593
12,413
15,319
19,723
18,037
23,315
25,399
0
8,131
6,990
4,378
5,905
4,302
5,592
2,206
1,778
2,251
1,176
2,810
3,453
3,762
3,118
4,109
3,344
3,3444,1093,1183,7623,4532,8101,1762,2511,7782,2065,5924,3025,9054,3786,9908,131025,39923,31518,03719,72315,31912,41314,59310,51410,4428,32921,3394,9293,8395,0635,62114,7178,31411,5699,8677,38511,59912,07015,75613,9236,49222,6003,8412,6194761,2461,247000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
-3,841
-3,841
0
-102,164
-64,243
-55,621
-58,905
-42,860
-46,926
0
-32,250
0
-779
-859
-143,814
-212,297
0
863
869
2,328
4,659
5,849
7,331
9,778
11,231
11,371
14,698
0
0
0
16,190
2,485
4,060
5,176
8,492
11,374
15,671
17,274
19,076
23,070
23,937
26,429
27,616
29,605
29,60527,61626,42923,93723,07019,07617,27415,67111,3748,4925,1764,0602,48516,19000014,69811,37111,2319,7787,3315,8494,6592,3288698630-212,297-143,814-859-7790-32,2500-46,926-42,860-58,905-55,621-64,243-102,1640-3,841-3,8410000000000
   > Long-term Assets 
0
0
0
0
6,864
7,506
8,719
20,251
31,458
9,495
26,867
22,048
132,358
110,195
84,231
77,426
82,736
66,648
73,442
71,099
59,202
50,450
155,919
158,893
169,136
237,133
244,453
233,537
244,677
265,036
250,165
208,472
279,037
212,464
129,786
239,363
216,275
133,320
172,041
236,213
373,505
360,714
382,460
395,385
405,946
359,642
327,914
302,906
103,283
186,082
140,936
717,605
697,599
586,902
586,902697,599717,605140,936186,082103,283302,906327,914359,642405,946395,385382,460360,714373,505236,213172,041133,320216,275239,363129,786212,464279,037208,472250,165265,036244,677233,537244,453237,133169,136158,893155,91950,45059,20271,09973,44266,64882,73677,42684,231110,195132,35822,04826,8679,49531,45820,2518,7197,5066,8640000
       Property Plant Equipment 
3,222
0
0
0
3,565
4,092
3,818
3,551
3,758
3,452
3,210
3,677
6,386
14,297
19,328
21,127
23,220
22,950
25,134
26,261
25,337
24,139
24,771
24,019
24,431
23,732
24,134
24,613
24,320
81,742
121,516
119,893
126,108
126,161
123,926
121,124
117,542
111,722
107,828
103,174
104,230
101,978
97,660
93,130
88,116
83,959
79,500
73,947
69,791
65,725
61,476
57,660
54,554
50,928
50,92854,55457,66061,47665,72569,79173,94779,50083,95988,11693,13097,660101,978104,230103,174107,828111,722117,542121,124123,926126,161126,108119,893121,51681,74224,32024,61324,13423,73224,43124,01924,77124,13925,33726,26125,13422,95023,22021,12719,32814,2976,3863,6773,2103,4523,7583,5513,8184,0923,5650003,222
       Long Term Investments 
0
0
0
0
0
0
0
13,412
27,125
5,005
22,631
17,917
125,382
95,258
64,243
55,621
58,905
42,860
46,926
43,499
32,250
23,423
129,899
133,804
143,814
212,297
219,724
208,508
220,119
183,234
128,649
88,579
152,929
84,503
4,285
116,889
97,608
21,598
61,313
130,139
266,375
255,836
280,845
298,352
313,874
271,727
244,357
224,902
29,435
116,301
75,404
655,889
638,321
531,253
531,253638,321655,88975,404116,30129,435224,902244,357271,727313,874298,352280,845255,836266,375130,13961,31321,59897,608116,8894,28584,503152,92988,579128,649183,234220,119208,508219,724212,297143,814133,804129,89923,42332,25043,49946,92642,86058,90555,62164,24395,258125,38217,91722,6315,00527,12513,4120000000
       Long-term Assets Other 
0
0
0
0
593
708
2,195
582
575
1,038
1,026
454
590
640
660
678
611
838
1,382
1,339
1,615
2,888
1,249
1,070
891
1,104
595
416
238
60
98,500
95,833
94,636
1,800
1,575
1,350
1,125
0
2,900
2,900
2,900
2,900
3,955
3,903
3,956
3,956
4,057
4,057
4,057
4,056
4,056
4,056
4,724
535,974
535,9744,7244,0564,0564,0564,0574,0574,0573,9563,9563,9033,9552,9002,9002,9002,90001,1251,3501,5751,80094,63695,83398,500602384165951,1048911,0701,2492,8881,6151,3391,3828386116786606405904541,0261,0385755822,1957085930000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
2,706
2,706
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000002,7062,706000000
> Total Liabilities 
131,330
0
0
0
93,110
88,733
82,380
76,474
69,723
60,569
71,482
61,859
67,538
47,519
70,218
73,429
74,947
63,744
268,523
270,593
260,503
249,936
251,608
237,394
238,894
174,532
175,093
168,866
170,920
201,874
251,193
250,325
250,213
174,439
417,676
427,997
453,452
191,804
152,787
146,736
145,761
128,406
128,397
130,150
137,904
114,772
120,917
120,415
126,099
105,787
112,553
165,122
122,243
88,990
88,990122,243165,122112,553105,787126,099120,415120,917114,772137,904130,150128,397128,406145,761146,736152,787191,804453,452427,997417,676174,439250,213250,325251,193201,874170,920168,866175,093174,532238,894237,394251,608249,936260,503270,593268,52363,74474,94773,42970,21847,51967,53861,85971,48260,56969,72376,47482,38088,73393,110000131,330
   > Total Current Liabilities 
48,158
0
0
0
35,113
37,031
36,979
37,377
36,930
34,081
44,638
35,084
61,089
36,379
45,198
49,756
52,888
45,055
67,264
78,003
88,433
82,429
93,648
88,112
94,941
74,699
84,870
84,746
93,503
80,907
89,504
92,432
92,886
69,858
64,353
69,771
94,394
96,504
60,649
57,896
59,826
45,792
48,396
53,596
62,629
45,113
55,141
58,425
67,955
51,691
62,637
119,451
81,156
52,366
52,36681,156119,45162,63751,69167,95558,42555,14145,11362,62953,59648,39645,79259,82657,89660,64996,50494,39469,77164,35369,85892,88692,43289,50480,90793,50384,74684,87074,69994,94188,11293,64882,42988,43378,00367,26445,05552,88849,75645,19836,37961,08935,08444,63834,08136,93037,37736,97937,03135,11300048,158
       Short-term Debt 
0
0
0
0
6,668
7,171
8,831
10,021
8,171
3,974
5,598
10,004
14,330
16,716
9,389
6,240
4,699
1,949
183,540
0
154,297
0
0
0
125,798
81,831
0
0
59,809
18,256
12,794
14,596
6,915
13,544
13,962
14,388
14,820
8,309
19,542
20,590
11,159
23,988
24,446
26,850
13,663
27,984
28,652
29,328
30,016
15,407
31,720
16,319
16,781
17,196
17,19616,78116,31931,72015,40730,01629,32828,65227,98413,66326,85024,44623,98811,15920,59019,5428,30914,82014,38813,96213,5446,91514,59612,79418,25659,8090081,831125,798000154,2970183,5401,9494,6996,2409,38916,71614,33010,0045,5983,9748,17110,0218,8317,1716,6680000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,128
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000009,12800000000000000000000000000000
       Accounts payable 
3,573
0
0
0
3,308
4,737
3,038
2,140
3,678
4,411
5,388
6,225
11,067
12,640
8,914
8,971
14,748
13,746
18,448
15,424
17,106
16,152
23,409
17,899
22,767
17,932
17,320
16,616
17,880
12,413
15,435
21,511
21,896
18,707
15,461
12,853
17,724
51,224
7,654
10,308
16,700
11,551
7,790
10,415
18,616
8,662
11,626
13,271
9,780
11,155
10,035
17,143
16,643
13,726
13,72616,64317,14310,03511,1559,78013,27111,6268,66218,61610,4157,79011,55116,70010,3087,65451,22417,72412,85315,46118,70721,89621,51115,43512,41317,88016,61617,32017,93222,76717,89923,40916,15217,10615,42418,44813,74614,7488,9718,91412,64011,0676,2255,3884,4113,6782,1403,0384,7373,3080003,573
       Other Current Liabilities 
26,718
0
0
0
1,858
2,171
3,728
4,908
6,718
102
1,765
6,171
10,495
16,853
4,287
11,895
13,776
12,837
-166,193
26,164
-118,883
28,587
33,170
34,346
-91,466
-64,276
26,418
25,989
-16,896
28,071
42,821
39,452
53,142
32,859
34,930
42,530
61,850
23,601
26,283
18,939
31,967
7,753
16,160
16,331
30,350
8,467
14,863
15,826
28,159
25,129
20,882
33,307
63,642
20,761
20,76163,64233,30720,88225,12928,15915,82614,8638,46730,35016,33116,1607,75331,96718,93926,28323,60161,85042,53034,93032,85953,14239,45242,82128,071-16,89625,98926,418-64,276-91,46634,34633,17028,587-118,88326,164-166,19312,83713,77611,8954,28716,85310,4956,1711,7651026,7184,9083,7282,1711,85800026,718
   > Long-term Liabilities 
0
0
0
0
57,997
51,702
45,401
39,097
32,793
26,488
26,844
26,775
6,449
11,140
25,020
23,673
22,059
18,689
201,259
192,590
172,070
167,507
157,960
149,282
143,953
99,833
90,223
84,120
77,417
120,967
161,689
157,893
157,327
104,581
353,323
358,226
359,058
95,300
92,138
88,840
85,935
82,614
80,001
76,554
75,275
69,659
65,776
61,990
58,144
54,096
49,916
45,671
41,087
36,624
36,62441,08745,67149,91654,09658,14461,99065,77669,65975,27576,55480,00182,61485,93588,84092,13895,300359,058358,226353,323104,581157,327157,893161,689120,96777,41784,12090,22399,833143,953149,282157,960167,507172,070192,590201,25918,68922,05923,67325,02011,1406,44926,77526,84426,48832,79339,09745,40151,70257,9970000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
673
571
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000057167300000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-6,668
-7,171
-8,831
-10,021
-8,171
-3,974
-5,598
-10,004
-14,330
-16,716
-9,389
-6,240
-4,699
-1,949
-183,540
0
-154,297
0
0
0
-125,798
-81,831
0
0
-59,809
56,878
103,676
100,798
106,747
97,809
95,384
92,911
90,379
95,300
82,367
78,545
85,935
70,620
66,723
62,074
71,996
54,354
50,294
46,170
41,980
52,940
32,900
44,515
40,207
35,744
35,74440,20744,51532,90052,94041,98046,17050,29454,35471,99662,07466,72370,62085,93578,54582,36795,30090,37992,91195,38497,809106,747100,798103,67656,878-59,80900-81,831-125,798000-154,2970-183,540-1,949-4,699-6,240-9,389-16,716-14,330-10,004-5,598-3,974-8,171-10,021-8,831-7,171-6,6680000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
2,706
2,706
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000002,7062,706000000
       Long-term Liabilities Other 
0
0
0
0
0
0
10
262
6
3
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66,294
59,809
0
0
0
157,327
0
250,958
258,121
359,058
0
92,138
88,840
85,935
82,614
80,001
76,554
3,279
69,659
65,776
1,156
1,156
1,156
1,156
1,156
880
880
8808801,1561,1561,1561,1561,15665,77669,6593,27976,55480,00182,61485,93588,84092,1380359,058258,121250,9580157,32700059,80966,294000000000000000023626210000000
       Deferred Long Term Liability 
0
0
0
0
0
0
45,103
38,835
32,567
26,485
26,842
26,775
6,449
11,140
25,020
23,673
22,059
18,689
201,259
192,590
172,070
167,507
157,960
149,282
143,953
99,833
90,223
17,826
17,608
0
0
0
0
571
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000571000017,60817,82690,22399,833143,953149,282157,960167,507172,070192,590201,25918,68922,05923,67325,02011,1406,44926,77526,84226,48532,56738,83545,103000000
> Total Stockholder Equity
63,140
0
0
0
43,898
37,120
28,872
142,595
131,482
121,343
200,548
207,749
424,366
426,817
404,165
375,657
345,118
332,373
289,078
401,449
358,591
307,380
508,992
449,806
375,503
865,594
823,142
760,213
687,537
620,257
532,677
448,291
640,528
625,299
558,465
480,452
399,500
2,296,630
1,721,816
1,394,762
1,291,975
1,207,453
1,124,070
1,050,170
1,100,814
1,036,526
964,236
886,843
811,019
743,922
660,510
1,626,672
1,540,956
1,466,528
1,466,5281,540,9561,626,672660,510743,922811,019886,843964,2361,036,5261,100,8141,050,1701,124,0701,207,4531,291,9751,394,7621,721,8162,296,630399,500480,452558,465625,299640,528448,291532,677620,257687,537760,213823,142865,594375,503449,806508,992307,380358,591401,449289,078332,373345,118375,657404,165426,817424,366207,749200,548121,343131,482142,59528,87237,12043,89800063,140
   Common Stock
3
0
0
0
3
23
4
31
31
32
34
35
37
37
37
38
38
38
38
42
42
42
48
49
49
58
58
58
58
59
59
59
68
69
69
69
69
70
70
71
71
71
71
71
71
72
72
72
72
73
73
73
73
74
747373737372727272717171717171707069696969685959595858585849494842424238383838373737353432313142330003
   Retained Earnings Total Equity0000000-635,385-551,579-470,561-507,087-425,340-333,534-238,760-144,133-55,3670-1,843,475-1,745,818-1,646,839-1,556,361-1,516,105-1,413,755-1,307,582-1,197,711-1,104,633-1,012,839-918,175-849,430-798,061-709,776-632,639-549,557-483,151-426,665-363,831-307,878-284,680-244,057-203,802-171,905-166,948-140,284-143,988-125,692-113,444-101,062-89,885000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-2
-1
-5
25
14
33
12
51
-57
191
222
225
-318
89
297
29
-313
-212
-650
-515
-1,389
-2,643
-2,398
-2,119
-2,171
-484
490
464
202
74
1,636
663
105
-3
-144
-198
-1,198
-7,745
-10,502
-15,083
-12,535
-8,411
-8,870
-5,896
-441
-1,087
-1,045
3,420
-1,518
365
365-1,5183,420-1,045-1,087-441-5,896-8,870-8,411-12,535-15,083-10,502-7,745-1,198-198-144-31056631,63674202464490-484-2,171-2,119-2,398-2,643-1,389-515-650-212-3132929789-318225222191-575112331425-5-1-20000
   Capital Surplus 
0
0
0
0
0
0
2,836
243,601
244,881
246,970
344,490
347,947
591,334
598,494
607,708
619,451
630,078
640,124
652,574
828,043
842,013
857,107
1,142,233
1,160,048
1,174,904
1,717,609
1,743,657
1,775,113
1,794,283
1,818,393
1,839,710
1,861,523
2,156,363
2,181,517
2,203,599
2,225,538
2,242,801
0
2,306,304
2,322,460
2,334,348
2,351,147
2,362,327
2,374,755
2,386,325
2,398,930
2,410,905
0
0
0
0
0
0
0
00000002,410,9052,398,9302,386,3252,374,7552,362,3272,351,1472,334,3482,322,4602,306,30402,242,8012,225,5382,203,5992,181,5172,156,3631,861,5231,839,7101,818,3931,794,2831,775,1131,743,6571,717,6091,174,9041,160,0481,142,233857,107842,013828,043652,574640,124630,078619,451607,708598,494591,334347,947344,490246,970244,881243,6012,836000000
   Treasury Stock0000000-802,486-802,486-802,486-802,486-802,486-802,486-802,486-783,438-529,04700000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
2,012
118,363
2,836
243,601
244,881
246,970
344,490
347,947
591,334
598,494
607,708
619,451
630,078
640,124
652,574
828,043
842,013
857,107
1,142,233
1,160,048
1,174,904
1,717,609
1,743,657
1,775,113
1,794,283
1,818,393
1,839,710
1,861,523
2,156,363
2,181,517
2,203,599
2,225,538
2,242,801
2,265,713
1,777,257
1,539,022
1,531,862
1,548,661
1,559,841
1,572,269
1,583,839
1,596,444
1,608,419
1,619,376
1,634,037
1,649,134
1,661,798
1,675,580
1,691,325
1,704,302
1,704,3021,691,3251,675,5801,661,7981,649,1341,634,0371,619,3761,608,4191,596,4441,583,8391,572,2691,559,8411,548,6611,531,8621,539,0221,777,2572,265,7132,242,8012,225,5382,203,5992,181,5172,156,3631,861,5231,839,7101,818,3931,794,2831,775,1131,743,6571,717,6091,174,9041,160,0481,142,233857,107842,013828,043652,574640,124630,078619,451607,708598,494591,334347,947344,490246,970244,881243,6012,836118,3632,0120000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue36,498
Cost of Revenue-4,165
Gross Profit32,33332,333
 
Operating Income (+$)
Gross Profit32,333
Operating Expense-458,070
Operating Income-425,737-425,737
 
Operating Expense (+$)
Research Development301,286
Selling General Administrative156,784
Selling And Marketing Expenses0
Operating Expense458,070458,070
 
Net Interest Income (+$)
Interest Income48,083
Interest Expense-0
Other Finance Cost-0
Net Interest Income48,083
 
Pretax Income (+$)
Operating Income-425,737
Net Interest Income48,083
Other Non-Operating Income Expenses0
Income Before Tax (EBT)717,969-1,569,443
EBIT - interestExpense = -431,390
717,969
673,725
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-431,390717,969
Earnings Before Interest and Taxes (EBITDA)-425,737
 
After tax Income (+$)
Income Before Tax717,969
Tax Provision-44,244
Net Income From Continuing Ops673,725673,725
Net Income673,725
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses462,235
Total Other Income/Expenses Net1,143,706-48,083
 

Technical Analysis of Agios
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Agios. The general trend of Agios is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Agios's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Agios Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Agios Pharm.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 43.25 < 52.09 < 62.45.

The bearish price targets are: 36.39 > 36.17 > 32.90.

Know someone who trades $AGIO? Share this with them.👇

Agios Pharm Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Agios Pharm. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Agios Pharm Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Agios Pharm. The current macd is 1.57769826.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Agios price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Agios. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Agios price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Agios Pharm Daily Moving Average Convergence/Divergence (MACD) ChartAgios Pharm Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Agios Pharm. The current adx is 34.68.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Agios shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Agios Pharm Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Agios Pharm. The current sar is 34.24.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Agios Pharm Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Agios Pharm. The current rsi is 70.00. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending down: The RSI is trending down. -1
Agios Pharm Daily Relative Strength Index (RSI) ChartAgios Pharm Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Agios Pharm. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Agios price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Agios Pharm Daily Stochastic Oscillator ChartAgios Pharm Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Agios Pharm. The current cci is 199.47.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Agios Pharm Daily Commodity Channel Index (CCI) ChartAgios Pharm Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Agios Pharm. The current cmo is 46.10.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Agios Pharm Daily Chande Momentum Oscillator (CMO) ChartAgios Pharm Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Agios Pharm. The current willr is -13.42192691.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Agios Pharm Daily Williams %R ChartAgios Pharm Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Agios Pharm.

Agios Pharm Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Agios Pharm. The current atr is 1.54240479.

Agios Pharm Daily Average True Range (ATR) ChartAgios Pharm Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Agios Pharm. The current obv is 8,163,451.

Agios Pharm Daily On-Balance Volume (OBV) ChartAgios Pharm Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Agios Pharm. The current mfi is 64.64.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Agios Pharm Daily Money Flow Index (MFI) ChartAgios Pharm Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Agios Pharm.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-14MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-29STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-10STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Agios Pharm Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Agios Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5070.000
Ma 20Greater thanMa 5035.197
Ma 50Greater thanMa 10032.497
Ma 100Greater thanMa 20031.535
OpenGreater thanClose38.850
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Agios with someone you think should read this too:
  • Are you bullish or bearish on Agios? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Agios? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Agios Pharm

I send you an email if I find something interesting about Agios Pharm.


Comments

How you think about this?

Leave a comment

Stay informed about Agios Pharm.

Receive notifications about Agios Pharm in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.